CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.31 EUR | +3.16% |
|
-2.52% | -20.51% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
| Sales 2022 | - | Sales 2023 | 102K 111K | Capitalization | 16.16M 17.54M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -43.42M | Net income 2023 | -8M -8.68M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.23M | Net cash position 2023 | 5.95M 6.45M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | +3.16% | ||
| 1 week | -2.52% | ||
| Current month | -4.62% | ||
| 1 month | -7.46% | ||
| 3 months | -16.22% | ||
| 6 months | -38.00% | ||
| Current year | -20.51% |
1 week
0.30
0.32
1 month
0.290.34
Current year
0.290.47
1 year
0.291.28
3 years
0.295.20
5 years
0.2918.44
10 years
0.2970.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 0.31 | +3.16% | 13,904 |
| 24-05-27 | 0.3005 | 0.00% | 12,630 |
| 24-05-24 | 0.3005 | -3.06% | 7,139 |
| 24-05-23 | 0.31 | -2.82% | 4,643 |
| 24-05-22 | 0.319 | +6.16% | 8,910 |
Real-time Euronext Bruxelles, May 28, 2024 at 11:12 am EDT
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-09-20
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.51% | 13.52M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
- Stock Market
- Equities
- CYAD Stock
